Global brain cancer incidence has risen modestly over the past three decades, climbing from roughly 3.75 to about 4.28 new cases per 100,000 people between 1990 and 2021. But that single trend line obscures a more complicated picture involving better imaging technology, shifting tumor classifications, aging populations, and genuine questions about environmental exposures. Whether the increase reflects a true biological shift or something closer to a measurement artifact depends on which tumor type, which country, and which time window you examine.
What the Global Numbers Actually Show
Multiple large analyses drawing on the Global Burden of Disease database agree on the direction: age-standardized incidence rates for brain and central nervous system cancers have trended upward since 1990. One study covering 1990 to 2019 reported a global age-standardized incidence rate of about 4.34 per 100,000, representing a roughly 14% cumulative increase over three decades, though the confidence interval around that estimate was wide.1Archives of Public Health. Burden and trends of brain and central nervous system cancer from 1990 to 2019 at the global, regional, and country levels A newer analysis extending through 2021 found a similar trajectory, with the rate climbing from 3.75 to 4.28 per 100,000.2PubMed Central. Epidemiological trends of burden of brain and CNS cancer at global, regional, and national level: a trend analysis study from 1990 to 2021
That same analysis, however, uncovered an important wrinkle using joinpoint regression, a statistical tool that identifies when a trend changes direction. After decades of steady climbing, both incidence and prevalence actually declined between 2018 and 2021.3PubMed Central. The global, regional, and national brain and CNS cancers burden and trends from 1990 to 2021 Whether that recent dip represents a genuine plateau, a temporary fluctuation, or a data lag during the COVID-19 pandemic years remains an open question. The overall picture since 1990 is a slow upward drift, not a dramatic surge, with signs that the climb may be leveling off.
How Much of the Rise Is an Artifact of Better Detection
The increase in diagnosed brain tumors coincided almost perfectly with the explosion of CT scanning and MRI availability worldwide. This has been a central debate in neuro-oncology for decades. A landmark study from the early 1990s tried to quantify exactly how much of the apparent rise was due to new imaging. Researchers re-evaluated patient records from an era before CT and MRI were routine and found that about 20% of brain tumors went undetected without those tools, while 10% of cases originally labeled as brain tumors were actually misdiagnoses. The authors concluded that improved imaging accounted for a meaningful share of the trend but not all of it.4JNCI: Journal of the National Cancer Institute. Increasing Incidence of Primary Malignant Brain Tumors: Influence of Diagnostic Methods
More recent work from Wales and the United States reinforced this pattern. Brain MRI use roughly doubled in parts of the UK during the 2000s, and brain MRI performed for unrelated reasons picks up incidental tumors in about 1.4% of scans. Regional differences in neuroimaging access correlate with regional differences in reported brain tumor incidence, which strongly suggests that at least part of the international variation in rates is a function of how hard you look.5Neuro-Oncology. Might changes in diagnostic practice explain increasing incidence of brain and central nervous system tumors? A population-based study in Wales (United Kingdom) and the United States
Registry changes add another layer. In the United States, a 2002 federal law required cancer registries to begin reporting non-malignant brain tumors for the first time. After the law took effect, recorded rates of non-malignant meningiomas climbed steeply, not because more people were developing them, but because they were finally being counted.6Cancer. Epidemiology of meningiomas post‐Public Law 107‐206: The Benign Brain Tumor Cancer Registries Amendment Act Anyone looking at raw trend data without accounting for that policy change would incorrectly conclude that meningiomas were skyrocketing.
Glioblastoma Trends Tell a Split Story
Glioblastoma is the most aggressive primary brain tumor, and its trends attract the most attention. The answer here depends on whether you are looking at age-adjusted rates or raw case counts. An analysis of England’s population data found that age-adjusted glioblastoma incidence is stable, even though the absolute number of cases keeps climbing.7PubMed. Adult glioblastoma in England: Incidence, treatment, and outcomes with novel population-based strata That distinction matters: more elderly people in the population means more glioblastoma cases, without any individual person being at greater risk.
A U.S. study covering 1973 to 2014 found that glioblastoma and non-glioblastoma brain tumors moved in opposite directions. Glioblastoma incidence rose, while lower-grade glioma incidence fell, suggesting that better pathology and molecular testing were reclassifying some tumors that would previously have been called lower-grade into the glioblastoma category.8Cancer Medicine. Trends and patterns of incidence of diffuse glioma in adults in the United States, 1973‐2014 The same study found a striking birth-cohort effect: people born in the 1920s had roughly four times the glioblastoma risk of those born in the 1890s, even after adjusting for age and diagnostic era. That points to something beyond imaging changes, possibly environmental or lifestyle exposures that shifted over the twentieth century.
Meanwhile, a smaller study from a single well-defined population reported a sharp jump in glioblastoma incidence over just a decade, from about 0.73 per 100,000 in 2008 to 4.49 in 2017.9PubMed Central. Rising Incidence of Glioblastoma Multiforme in a Well-Defined Population Numbers from a single small region should be interpreted cautiously, since year-to-year variation in a rare cancer can be dramatic, but the finding adds to the sense that glioblastoma trends deserve continued monitoring.
Childhood Brain Tumors Have Been Stable for Decades
Brain tumors are the most common solid tumor and the leading cause of cancer death in children and adolescents in the United States.10PubMed Central. CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018 That sounds alarming, but the incidence rate itself has been essentially flat since the late 1980s. A study tracking childhood brain tumors from 1973 to 2009 documented a dramatic 53% spike in incidence between 1983 and 1986, followed by more than two decades of stable rates. The mid-1980s spike aligns neatly with the widespread adoption of CT and MRI in pediatric medicine, and a closer look at the subtypes confirmed this: the rate of increase in one specific low-grade tumor mirrored the rate of decrease in a broader, less specific category, suggesting tumors were being reclassified rather than newly created.11PubMed Central. Trends in childhood brain tumor incidence, 1973-2009
For parents anxious about rising cancer rates, the data is genuinely reassuring on this front. The risk of a child developing a brain tumor has not measurably changed in over 20 years. What has changed is our ability to detect and classify those tumors with greater precision.
More Diagnoses, Fewer Deaths
One of the more telling patterns in the data is the divergence between incidence and mortality. Globally, brain cancer diagnoses have risen in both men and women, with incidence climbing at roughly half a percent per year for each sex. But mortality has actually ticked downward in women, and has remained essentially flat in men.12PubMed Central. International patterns and trends in the brain cancer incidence and mortality: An observational study based on the global burden of disease That gap is consistent with the detection-driven-increase hypothesis: if better imaging is catching more tumors, including smaller or slower-growing ones, you would expect incidence to climb while death rates stay flat or improve.
Some of the mortality improvement also reflects genuine advances in treatment, including more targeted surgery, refined radiation techniques, and a slowly expanding toolkit of chemotherapy and immunotherapy options. But prognosis for the most aggressive tumors like glioblastoma remains poor, and overall survival gains for brain cancer lag far behind progress in many other cancer types. The incidence-mortality gap is more about catching tumors that would never have killed the patient than about curing the lethal ones.
The Geography Problem
Global averages hide enormous geographic variation that says as much about healthcare infrastructure as it does about disease. In 2021, Norway had the world’s highest age-standardized incidence rate at about 15 per 100,000, while Gambia’s was roughly 0.14, a more than 100-fold difference.3PubMed Central. The global, regional, and national brain and CNS cancers burden and trends from 1990 to 2021 That gap does not mean brain tumors are a hundred times more common in Scandinavia. It means that in low-resource settings, the absence of neuroimaging, limited pathology services, and fragmented cancer surveillance systems produce massive underdiagnosis and underreporting.
A separate analysis of over 200 tumor registries worldwide confirmed the pattern: apparent incidence ran about 6.76 per 100,000 in Europe versus 2.81 in Africa, and high-income countries consistently reported higher rates than low- and middle-income countries.13PubMed. Global incidence of brain and spinal tumors by geographic region and income level based on cancer registry data These numbers should be read as floor estimates in lower-income regions, not as evidence that people there are biologically protected. As diagnostic capacity expands globally, reported brain cancer incidence in currently underserved regions will almost certainly rise, even if the underlying risk stays the same.
Why Population Aging Matters More Than You Might Think
Brain tumors, particularly glioblastoma, become more common with age. As life expectancy has increased and populations have grown older worldwide, the absolute number of brain cancer cases has risen simply because more people are living into the age range where these tumors tend to appear. Decomposition analyses that separate out the effects of population growth, aging, and true epidemiological change have found that population growth and aging together account for the bulk of the increase in brain cancer cases, deaths, and disability over the past three decades.14PubMed Central. Global, regional, and national burden of brain and other central nervous system cancers from 1990 to 2021, and projections to 2035: a systematic analysis for the global burden of disease study 2021
This is a subtle but critical distinction. A country can see brain cancer case counts rise year after year while the age-adjusted rate, which accounts for how old the population is, stays completely flat. Both statements are true simultaneously, but they tell very different stories. Anyone citing raw case numbers without age adjustment is overstating the trend.
Cell Phones and Brain Cancer
No discussion of brain cancer trends is complete without addressing cell phones, which remain the single most commonly asked-about risk factor. The evidence at this point is extensive and consistently negative. The UK Million Women Study followed over 776,000 women for 14 years and found no increased risk of brain tumors with cell phone use, including among women who had used phones for over a decade or those who used them heavily. Even for gliomas in the temporal and parietal lobes, the brain regions closest to a held handset, risk was slightly below 1.0.15PubMed Central. Cellular Telephone Use and the Risk of Brain Tumors: Update of the UK Million Women Study
The COSMOS prospective cohort study, which used objective operator data rather than relying on people’s memory of their phone habits, found no association between cumulative call time and glioma, meningioma, or acoustic neuroma. Even among the heaviest users, the risk estimates hovered around 1.0.16PubMed. Mobile phone use and brain tumour risk – COSMOS, a prospective cohort study And the Danish cohort study, one of the largest and longest-running analyses on this topic, found incidence rate ratios consistently close to 1.0 for both men and women, with no dose-response relationship and no increase in tumors near where phones are held.17BMJ. Use of mobile phones and risk of brain tumours: update of Danish cohort study
If mobile phones were a meaningful cause of brain cancer, the dramatic worldwide increase in phone use since the mid-1990s should have produced a visible uptick in brain tumor rates decades ago, particularly in the temporal lobe. That uptick has not materialized. The cell phone question is, at this point, one of the most thoroughly investigated hypotheses in cancer epidemiology, and it keeps returning the same answer.
Environmental Exposures That Actually Have Evidence Behind Them
While cell phones have been cleared, a few environmental factors carry genuine, if modest, associations with brain tumor risk. The strongest established cause is ionizing radiation. A large study of children who received CT scans found that brain cancer incidence rose with cumulative radiation dose to the brain. The researchers estimated that about 40% of brain tumors diagnosed more than two years after childhood CT exposure were attributable to the radiation itself, not to whatever condition prompted the scan.18PubMed Central. Computed tomography scan radiation and brain cancer incidence This does not mean CT scans are dangerous in any absolute sense, since brain cancer remains rare even in irradiated populations, but it reinforces the principle of minimizing unnecessary scans, especially in children.
Pesticide exposure has a more ambiguous evidence base. A meta-analysis of studies focused on farmers found that documented pesticide use in farming was associated with roughly a 20% elevated risk of brain cancer.19PubMed Central. Farming, Pesticides, and Brain Cancer: A 20-Year Updated Systematic Literature Review and Meta-Analysis But the picture gets murkier when you look at individual pesticide types. A case-control study found no association between insecticide or herbicide exposure and glioma in either sex. The exception was women who reported herbicide use, who had a significantly elevated risk of meningioma, with the risk climbing with longer and heavier exposure.20PubMed Central. Occupational exposure to pesticides and risk of adult brain tumors In men, there was no such association. The inconsistency across studies and subgroups makes it hard to issue blanket warnings, though the overall weight of evidence suggests occupational pesticide exposure deserves continued scrutiny.
Air pollution is an emerging area of investigation. A systematic review and meta-analysis found that long-term exposure to certain pollutants, particularly ozone and fine particulate matter absorbance, was associated with a modestly elevated risk of brain tumors, though results varied by pollutant type and not all associations reached statistical significance.21PubMed Central. The Relationship between Air Pollution and Brain Cancer: A Systematic Review and Meta-Analysis A large Taiwanese cohort study found that people exposed to the highest levels of certain air pollutants, including carbon monoxide, nitrogen dioxide, and fine particulate matter, had a roughly 30-40% higher risk of benign brain tumors compared to those in the lowest exposure group.22Toxics. Long-Term Exposure to Air Pollution Associates the Risk of Benign Brain Tumor: A Nationwide, Population-Based, Cohort Study in Taiwan The research is still early-stage and the effect sizes are small, but the consistency of direction across studies is worth tracking.
How Classification Changes Muddy the Trend Data
Brain tumors are classified differently today than they were even a decade ago. The World Health Organization overhauled its brain tumor classification system in 2016 and again in 2021, incorporating molecular markers alongside traditional microscopic appearance. Under the old system, two tumors that looked identical under a microscope were given the same diagnosis. Under the new system, their molecular profiles might place them in entirely different categories, with different expected behaviors and different treatment implications.
This matters for trend analysis because cancer registries have struggled to keep pace with these changes. Registry reporting standards have lagged behind the current classification systems, meaning that data collected under one set of definitions gets compared to data collected under another.23Neuro-Oncology. Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States A tumor that was counted as glioblastoma in 2010 might be classified as a different entity entirely under 2021 criteria. When researchers compare rates across decades, they are often comparing categories that shifted underneath them. This does not invalidate the trend data, but it adds a layer of noise that makes precision difficult.
Incidental Findings and the Tumors We Never Would Have Known About
As imaging has become more routine, a growing proportion of brain tumors are discovered accidentally in people scanned for headaches, dizziness, or completely unrelated reasons. Brain metastases from cancers that originated elsewhere in the body affect an estimated 20% to 40% of cancer patients, and many of these are found on scans rather than through symptoms.24PubMed Central. Brain metastasis from an unknown primary, or primary brain tumour? A diagnostic dilemma
The phenomenon of incidental tumors is especially well documented for vestibular schwannomas, benign tumors of the nerve that connects the inner ear to the brain. A study tracking these tumors in the United States found that the incidence of incidentally discovered schwannomas rose at about 6.3% per year over two decades, even after the rate of head MRIs plateaued. The tumors being found incidentally were not getting smaller over time, which argues against the simple explanation that better-resolution scanners were just spotting tinier growths.25PubMed Central. Rising incidence of sporadic vestibular schwannoma: True biological shift versus simply greater detection The authors suggested that something beyond imaging availability may be contributing to the rise, though pinpointing what has proven difficult.
Incidental findings create a genuine clinical dilemma. Many small, slow-growing brain tumors found on scans would never have caused symptoms during a person’s lifetime. Discovering them leads to anxiety, repeated surveillance imaging, and sometimes surgery or radiation that carries its own risks. This overdiagnosis problem is well recognized in other cancers like thyroid and prostate, and brain tumors are not immune to it.
Genetic Predisposition and Hereditary Syndromes
A small but meaningful fraction of brain tumors are tied to inherited genetic conditions. Studies using modern sequencing have found that somewhere between 8% and 19% of children with CNS tumors carry an inherited change in a known tumor predisposition gene.26PubMed Central. Genetic syndromes predisposing to pediatric brain tumors Conditions like neurofibromatosis and Li-Fraumeni syndrome are the best-known examples. These syndromes are rare in the population, and they do not explain any of the trends in overall brain cancer incidence, since their frequency has not changed. But recognizing them matters for affected families, because genetic testing can guide surveillance and sometimes catch tumors earlier in relatives.
In adults, the genetic contribution is less well characterized. Family history of brain tumors modestly increases risk, though most adult brain cancers arise sporadically without any clear hereditary pattern. The expanding use of genetic testing is identifying more people with predisposition syndromes than were recognized in previous decades, but this represents improved detection of existing conditions rather than a new cause of brain cancer.27PubMed. Brain Cancers in Genetic Syndromes
Projections and What to Expect Going Forward
Several research groups have attempted to forecast brain cancer burden out to 2035 and 2040. The consensus projection is that absolute case counts will continue to rise, driven primarily by population growth and aging, while age-adjusted rates will remain relatively flat or increase only marginally.28PubMed Central. Global, regional, and national burden of brain and central nervous system cancer: a systematic analysis of incidence, deaths, and DALYS with predictions to 2040 Sub-Saharan Africa and South Asia are expected to see the steepest rises in raw numbers as life expectancy improves and diagnostic access expands.
These projections carry substantial uncertainty. They assume current trends in aging and healthcare access continue, and they cannot account for unknown environmental shifts or future changes in diagnostic criteria. What they do make clear is that the global healthcare system will be managing more brain cancer cases in coming decades regardless of whether the underlying risk per person changes. The practical challenge is not just figuring out whether brain cancer is “truly” increasing but ensuring that treatment capacity, diagnostic infrastructure, and research funding keep pace with the cases that are being found.